Infection by cytomegalovirus (CMV) may cause serious disease in immunocompromised adults, especially those persons who have undergone organ transplantation or those with AIDS [1] . It is estimated that CMV disease develops in ---20% of HIV-infected individuals within 2 years after the CD4 cell count falls below 100/mm 3 [2] .
Whereas retinal disease caused by CMV is distinctive and readily recognizable, pulmonary disease is not. Establishing the diagnosis of CMV pneumonia in patients with AIDS can be exceedingly difficult because of the following reasons: the clinical abnormalities are not distinctive [3] [4] [5] [6] , the virus may be cultured from pulmonary secretions in the absence of histologic evidence of disease [4, 7, 8] , and CMV is likely to coexist with other pulmonary pathogens [3, 6, [8] [9] [10] .
In one series of cases [6] , CMV was isolated from bronchoalveolar lavage (BAL) fluid specimens from about one-half of HIV-infected persons at the time that they were first found to have Pneumocystis carinii pneumonia (PCP) but was not thought to be causing disease since it had no effect on the outcome of pneumonia. As a result of these observations, CMV pneumonia has been considered to be uncommon in patients with AIDS.
A contrasting view exists in autopsy studies of patients with AIDS. Histologic evidence of CMV infection in the lungs was present in 29% to 93% of cases and was judged to have contrib-uted to death in 6% to 47% of these patients [11] [12] [13] [14] [15] [16] [17] [18] . On the basis of these findings, it is reasonable to hypothesize that the diagnosis of CMV pneumonia can be made during life and, further, that a therapeutic response to appropriate antiviral medication might be achieved, at least in some patients. Herein, we describe 17 patients with AIDS for whom CMV pneumonia was diagnosed during life on the basis of clinical, microbiological, and histologic evidence; these patients received specific antiviral therapy for this infection.
Methods
Patients and procedures. From 1 July 1991 to 30 April 1993, one pulmonologist (E.S.) performed ---210 bronchoscopies on HIV-infected patients to determine the cause of pulmonary infiltrates for which an etiology was not identified by noninvasive techniques. BAL fluid specimens, bronchial brushings, and transbronchial lung biopsy specimens were obtained from these patients. Brush tips and 2-3 mL ofBAL fluid were immediately placed into viral transport media.
BAL fluid specimens were stained by gram and auraminerhodamine fluorochrome stains and then cultured for the presence of bacteria (including Legionella), mycobacteria, fungi, and viruses. For viral cultures, each of three cell lines (human fetal foreskin or lung cells, HEp-2 or A 549 cells, and primary monkey kidney cells) was inoculated with the BAL fluid specimens. In addition, shell vials (MRC-5, Viromed, Minneapolis) were inoculated and then examined 16 and 36 hours later with use of fluorescent labeled antibody to CMV.
With use of a large forceps, at least three biopsy specimens were generally taken from areas of the lung that were determined to be the most involved by imaging procedures. Hematoxylin-eosin, Grocott-Gomori methenamine-silver nitrate, gram, Weigert's, and Ziehl-Neelsen stainings of all specimens were performed. Histologic and/or microbiological evaluation of other tissues was done as clinically indicated.
Pathology. For the purpose of this study, slides of lung tissue specimens were coded and evaluated by a pathologist (R.M.G.) who had not been involved in the care of these patients. Slides of negative control specimens from patients with AIDS who had other causes of pulmonary disease and who had no histologic or microbiological evidence of CMV disease were included in the study. Specimens were evaluated for the numbers of polymorphonuclear leukocytes, mononuclear cells, and viral inclusions to assess acute inflammation, chronic inflammation, and viral burden, respectively. These features were scored according to the following semiquantitative scale: 0, no inflammatory cells or viral inclusions; +, rare inflammatory cells or~1 viral inclusion per high-power field (magnification, X400); ++, moderate inflammatory cells or 2-9 viral inclusions per high-power field; and +++, dense inflammatory infiltrate or~10 viral inclusions per high-power field.
Immunohistochemical analysis and in situ hybridization. Lung tissue specimens were examined for the presence of immediate early, early, and late CMV antigens by an enhanced biotin-streptavidin method with use of a StrAviGen Sensitive Alkaline Phosphatase kit (Biogenex, San Ramon, CA) as previously described [19] . The presence of CMV-related DNA sequences in lung tissue specimens was determined by means of the Super Sensitive DNA Detection System (Biogenex) according to the recommendations of the manufacturer [19] . For immunohistochemical analysis and in situ hybridization, the intensity of staining was scored on a scale of 0 to +++, with o corresponding to no detectable reaction and +, ++, and +++ corresponding to~1, 2-9, and~10 positive cells per high-power field, respectively.
Results
Case identification. During the study period, CMV was isolated from pulmonary secretions from~50% of HIVinfected patients who underwent bronchoscopy. Seventeen of these patients met all of the following criteria for the diagnosis of CMV pneumonia: pulmonary infiltrate documented by chest roentgenogram; viral culture of SAL fluid or brush tip positive for CMV; and histologic evidence of CMV lung infection as demonstrated by typical intranuclear or intracytoplasmic inclusions. The medical records of these patients were reviewed in their entirety.
Clinical characteristics of subjects. The patients were all males, and their ages ranged from 28 to 52 years (mean age, 37.1 years). Previously documented AIDS-defining illnesses in these patients included PCP in 8, CMV retinitis in 6 (3 also with CMV infection of the gastrointestinal tract), Kaposi's sarcoma in 5, disseminated Mycobacterium avium complex (MAC) infection in 3, candidal esophagitis in 3, lymphoma in 2, CNS toxoplasmosis in 1, and salmonella sepsis in 1. Nine patients had two or more previously documented opportunistic infections or malignancies. CD4 cell counts obtained within 18 months of diagnosis of CMV pneumonia ranged from 0 to 59/mm 3 • At the time of presentation, all patients had fever (temperature, 38.3°C to 40.5°C), 13 had shortness of breath, 12 had cough, 11 had shortness of breath and cough, and 1 had chest pain. These symptoms were acute « 1 week) in six patients (two of whom presented with acute respiratory failure) and developed over a period of 1-4 weeks in 11. Two patients had no pulmonary symptoms.
Arterial blood gas pressures were measured while the patient was breathing room air in 12 cases; the Pao, ranged from 75
to 89 mm Hg in six patients and was <75 mm Hg in six. Chest roentgenograms showed interstitial patterns in 14 cases and a predominantly alveolar pattern in three. Disease was bilateral in 12 patients (diffuse in eight and bibasilar in four) and unilobar in five. Two patients had only unilateral perihilar infiltrates.
In two cases, a pleural effusion was also noted. Gallium scans of 10 of the 16 patients who underwent this study revealed abnormalities that corresponded to roentgenographic abnormalities in eight. Four and six patients had diffuse and localized increased lung uptake, respectively, that was described as mild to moderate in all but one patient. Pathology. In all 17 cases, reexamination of biopsied lung tissue confirmed the presence of characteristic CMV-infected cells with either nuclear or cytoplasmic inclusions; no specimens from non-CMV-infected controls showed cell inclusions. The degree of histologic evidence of CMV ranged from occasional to numerous inclusions in the tissue samples (table 1) . Twelve patients had interstitial pneumonitis (which was always characterized by mononuclear cells without polymorphonuclear leukocytes), 3 had changes of acute inflammation (indicated by a polymorphonuclear infiltrate; 2 of whom also had marked necrosis), and 2 had CMV inclusions without accompanying histologic changes of either acute or chronic inflammation.
Immunohistochemical analysis and in situ hybridization. Immunohistochemical analysis and in situ hybridization demonstrated the presence of CMV in 15 of 15 cases and 13 of 14 cases, respectively, in which enough tissue was available to perform these procedures (table 1). The correlation between the degree of viral burden estimated by these two techniques was excellent, as was the correlation between the number of cytomegalic cells estimated by these two procedures and that estimated by histology. For three cases in which histologic examination of lung specimens showed acute inflammatory changes, the viral burden determined by all assays was +++.
However, a correlation could not be identified in any of the other cases since chronic inflammation was nearly always mild (+), yet there was substantial variation in the viral burden.
CMV cultures. Cultures of bronchoscopically obtained specimens (15, SAL fluid; two, brush tip) yielded CMV in every case, with the shell vial assay being positive for 16 patients. Urine and blood cultures yielded CMV in one of five By definition, all patients had positive BAL fluid and/or brush tip cultures. Cases 1-9, patients for whom no other pulmonary pathogens were identified or cultured (group I); cases 10-17, patients for whom one or more pulmonary pathogens were detected by histopathologic examination and/or culture and none of 12 cases, respectively, in which these studies were done (table 1) . In three cases, cultures of bone marrow were negative for CMV. Analysis based on presence ofother potential causes ofpneumonia. In nine cases (group I patients), CMV was the only potentially pathogenic microorganism isolated from lung specimens by any of the microbiological or histologic techniques utilized; in the remaining eight cases (group II patients), one or more coexisting conditions may have contributed to the clinical syndrome (table 2) .
These two groups were indistinguishable on the basis of the duration and apparent severity of symptoms, degree of fever, abnormal blood gas pressures, and extent of radiographic pulmonary disease. There were no distinctive histopathologic changes that distinguished group I from group II patients (table  I) , although all three patients with acute inflammatory exudates were in group I.
The findings of intense inflammation and a heavy viral burden were associated with rapid deterioration and death in two patients (cases 1 and 6). The one patient in group I (case 9) who had a low-intensity infection determined by all staining procedures had a history of CMV retinitis and presented with worsening retinitis, pulmonary symptoms, and progressing pulmonary infiltrates in the absence of other pulmonary pathogens. He had a clinical and radiological response to treatment directed against CMV.
Of group I patients, 3 had CMV retinitis and gastrointestinal disease prior to the diagnosis of CMV pneumonia, 4 had CMV retinitis diagnosed at the same time that pneumonia was diagnosed (1 of whom also had cholecystitis and colitis), and 2 had CMV retinitis diagnosed within 3 months after CMV pneumonia was diagnosed. Ofgroup II patients, 3 had prior evidence of retinitis that was active at admission, 1 had gastrointestinal disease diagnosed concurrently with pneumonia, and 1 developed CMV retinitis within 4 months. Three of the group II patients (cases 10, 11, and 15) had no evidence of CMV infection elsewhere. These three patients had mild pneumonitis; there were few-to-moderate inclusions in two (cases 10 and 15), but one (case 11) had a high viral load determined by all methods used. The six patients (three each in groups I and II) who had prior CMV infection were all receiving treatment with recommended maintenance doses of ganciclovir or foscamet at the time that CMV pneumonia developed.
Response to treatment. All 17 patients were treated for CMV pneumonia with standard induction doses of ganciclovir (15 patients) or foscamet (two patients). Patients also received treatment directed against associated conditions (table 2) as clinically indicated. The conditions of six of the nine patients in group I improved clinically and radiologically during treatment, including the four who had retinitis. One patient was transferred to another facility. Two patients (cases 1 and 6) died within 2 weeks after CMV pneumonia was first diagnosed; at autopsy, both of these patients had CMV pneumonia without evidence of other pulmonary pathogens, although both had other disseminated infections, including one due to Cryptococcus neoformans (identified in liver and spleen) and one due to MAC (cultured from bone marrow).
Of the eight patients in group II, five had clinical and radiological improvement in their conditions. One of these patients (case 17) had relapses of CMV pneumonia and retinitis without evidence of another active infection 3 and 7 months, respectively, after the initial diagnosis. One patient died of PCP 2 months after treatment of CMV and pneumocystic infections; lung biopsy during the final admission showed no evidence of CMV. A third patient had progression of coexisting presumed CNS toxoplasmosis. Two patients were lost to follow-up. The three other patients in group II died during the hospitalization in which CMV pneumonia was diagnosed; their conditions that, together with CMV infection, were thought to contribute to death were PCP, disseminated MAC infection and lymphoma (both affecting the lungs), and candidal sepsis (cases 12, 13, and 16, respectively). Autopsies of these patients were not done. The overall mean survival ± SD after the diagnosis of CMV pneumonia was 3.1 ± 2.5 months (4.1 ± 3.0 months and 1.9 ± 1.1 months for group I and II patients, respectively; P = .11).
Discussion
CMV is cultured from BAL fluid specimens from 19% to 74% of HIV-infected patients undergoing bronchoscopy for evaluation of pulmonary disease [4-6, 8, 20, 21] . Whereas the finding of Mycobacterium tuberculosis or Histoplasma capsulatum in pulmonary secretions of a patient with AIDS is not likely to create a diagnostic or therapeutic dilemma, the isolation of CMV from the same source may leave substantial questions about its role in the pathogenesis of disease because of the following reasons: CMV can be cultured from body fluids of healthy [22] and immunocompromised patients in the absence of clinical disease [4, 7, 8, 23] ; in certain clinical settings, failure to treat patients from whom CMV is isolated from bronchial secretions has not been shown to alter outcome [4] [5] [6] [7] [8] 20] ; and some authorities hypothesize that CMV pneumonitis is caused by immunopathologic changes that do not occur in the presence of severe immunosuppression [24] . To establish a ern 1996;23 (July) definitive diagnosis of CMV lung disease, histologic evidence of infection is usually required [25] .
For our patients, diagnoses were based on radiographic evidence of pneumonia together with a culture of a BAL fluid specimen and/or brush tip that was positive for CMV and histopathologic evidence of CMV-induced changes in biopsied lung tissue. On the basis of these criteria, 17 (8%) of 210 HIVinfected patients who underwent bronchoscopy for evaluation of pulmonary infiltrates of unknown cause had CMV pneumonia. No features specifically suggested the diagnosis of CMV pneumonia except for advanced immunosuppression (CD4 cell counts of <60/mm 3 and prior evidence of other opportunistic infections or neoplasms in all patients) and documented CMV disease elsewhere. Radiographic findings were nonspecific. Interstitial infiltrates predominated in our cases, although an earlier review [26] found alveolar infiltrates most frequently. Cavitation, nodules, and effusion, each present in one patient in group I, have been previously noted [27, 28] . Consistent with results of other investigators [29] , blood and urine cultures for CMV were not helpful in diagnosing CMV disease.
The extent of lung injury caused by CMV infection ranged from minimal interstitial pneumonitis to severe diffuse alveolar damage. No inflammatory changes were observed in two cases. In transplant recipients who develop CMV pneumonitis, the severity of disease is thought to be related to the degree of inflammation but not to the viral burden estimated by conventional histologic techniques [24] .
Jacobson et al. [5] assessed the viral burden in AIDS patients from whom CMV was isolated from the lungs by the time that cultures ofBAL fluid became positive for CMV; they found that the time required for cultures to become positive did not correlate with survival. We examined the viral burden using three methods: histologic examination (the number of cells with CMV inclusions), immunohistochemical analysis (the presence of viral antigens), and in situ hybridization (the presence of viral genetic material). The degree of infection measured by these methods showed remarkably good correlation. In contrast, the degree of the associated inflammatory changes seemed to be unrelated to the viral burden, except in cases of severe acute pneumonia that were determined by histologic criteria. In the two cases in which autopsies were performed, severe pneumonitis was correlated with a high viral burden, as opposed to one case reported in the literature in which a high viral burden was associated with scanty signs of inflammation [30] .
All of our patients, including those who were already receiving maintenance anti-CMV therapy, were treated with induction doses of ganciclovir or foscamet. In the absence of ocular disease, a 3-week course of antiviral medication was given. Group II patients also received therapy for coexisting conditions. The conditions of a similar proportion of patients in groups I and II showed initial improvement with treatment. The overall rate of initial improvement (11 [65%] , of 17 patients) was comparable with the rates (70%-90%) reported for patients with CMV retinitis or gastrointestinal disease [31] . In nearly every case in which an initial response to treatment was observed, CMV disease in the lung or elsewhere eventually progressed despite maintenance treatment (a finding consistent with advancing immunosuppression, the inadequacy of maintenance regimens, and/or the development of viral resistance), and the overall survival was very poor.
In patients with AIDS and CD4 cell counts of < 100/mm 3 , the presence of pulmonary infiltrates for which an etiologic agent has not been determined or that are progressing despite treatment directed against some other identifiable pathogen should lead to consideration of a diagnosis of CMV pneumonia (especially if CMV infection is documented at any other site). About two-thirds of patients initially respond to treatment; however, in most cases, CMV disease is likely to eventually progress, thus helping to explain the relatively high frequency with which this condition has been diagnosed in postmortem studies.
In this series of cases (which were selected because CMV had been shown in tissues), the use of time-consuming and costly analyses, such as immunohistochemical analysis and in situ hybridization, confirmed the presence of CMV but did not provide further information. However, these techniques might have a role in identifying CMV infection in patients for whom examination of conventionally stained lung biopsy specimens has failed to demonstrate viral inclusions [32, 33] .
Detection of CMV DNA in BAL fluid by PCR amplification appears to be the most sensitive technique for detection of CMV infection [32, 34] , and in combination with immunostaining, PCR analysis appears to have a high specificity for the diagnosis of CMV pneumonia [32] . In addition, PCR techniques quantitating CMV DNA in BAL fluid [35] and lung tissue [36] have been used for predicting the development of and for diagnosing CMV pneumonia in transplant recipients, respectively. Well-controlled, prospective studies are needed to evaluate the usefulness of these antigen and DNA detection methods in discriminating which HIV-infected patients from whom CMV is isolated from pulmonary secretions are going to develop CMV disease.
